Navigation Links
Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
Date:9/14/2011

RICHMOND, Calif., Sept. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an overview of the company's business strategy at 7:30 am ET on Wednesday, September 21, 2011 at the UBS 2011 Global Life Sciences Conference which will be held in New York City.

In addition, Geoffrey Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development will review progress of Sangamo's ZFP Therapeutic® development programs, specifically data from the company's SB-728-T program for HIV/AIDS which are to be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011 in Chicago.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
2. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
3. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sangamo Announces Public Offering of Common Stock
7. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
8. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
9. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Md. , Feb. 10, 2016  The Maryland ... Busch , has announced that University of Maryland School ... PhD, MBA and University of Maryland Medical System President ... of the "Speaker,s Medallion," the highest honor given to ... of Delegates. Dean Reece and Mr. ...
(Date:2/10/2016)... 2016  IsoRay, Inc. (NYSE MKT: ISR), a medical ... radioisotope applications for the treatment of prostate, brain, lung, ... financial results for the second quarter and six months ... --> --> Revenue ... 2016, which ended December 31, 2015, a 12% increase ...
(Date:2/10/2016)... Springfield, MO (PRWEB) , ... February 10, 2016 ... ... company, will attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter ... of ISPE is expecting to fill more than 100 tables for its annual ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... on Microsoft Azure. On Azure, Arvados provides capabilities for managing and processing genomic ... for Microsoft Azure from major institutions collecting and analyzing genomic data,” said Adam ...
Breaking Biology Technology:
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized breaches ... to find new ways to ensure data security and ... iOS and Android that ties a ... transforming it into a hardware authorization token. Customer service ... their fingerprint on their KodeKey enabled device to verify ...
Breaking Biology News(10 mins):